利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

95 条记录 (耗时 0.042 秒)

    COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS
    71.
    发明申请
    COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS 审中-公开
    用于治疗下尿路症状的组合疗法

    公开(公告)号：US20100113469A1

    公开(公告)日：2010-05-06

    申请号：US12532731

    申请日：2008-03-25

    申请人： Tara Frenkl ,  Stuart A. Green ,  Enan Macintyre ,  Sander G. Mills

    发明人： Tara Frenkl ,  Stuart A. Green ,  Enan Macintyre ,  Sander G. Mills

    IPC分类号： A61K31/4439 ,  A61K31/58 ,  A61K31/439 ,  A61K31/445 ,  A61K31/403 ,  A61K31/454 ,  A61K31/46 ,  A61P13/00

    CPC分类号： A61K31/47 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention concerns compositions for the treatment of Lower Urinary Tract Symptoms (LUTS), and especially LUTS which results from benign prostatic hypertrophy. The compositions of the invention comprise a Beta-3 agonist described below, optionally in combination with a 5-alpha reductase inhibitor, or an NK-1 antagonist or an alpha-1 adrenergic antagonist or an anti-muscarinic agent. The invention also includes compositions comprising a beta-3 agonist and two additional active agents selected from a 5-alpha reductase inhibitor, an NK-1 antagonist, an alpha-1 adrenergic antagonist or an anti-muscarinic agent.

    摘要翻译： 本发明涉及用于治疗下尿路症状（LUTS）的组合物，特别是由良性前列腺肥大引起的LUTS。 本发明的组合物包含下述的β-3激动剂，任选地与5-α还原酶抑制剂或NK-1拮抗剂或α-1肾上腺素能拮抗剂或抗毒蕈碱剂组合。 本发明还包括包含β-3激动剂和选自5-α还原酶抑制剂，NK-1拮抗剂，α-1肾上腺素能拮抗剂或抗毒蕈碱剂的另外的活性剂的组合物。

    Substituted imidazoles as cannabinoid receptor modulators
    73.
    发明授权
    Substituted imidazoles as cannabinoid receptor modulators 失效
    取代的咪唑作为大麻素受体调节剂

    公开(公告)号：US07572785B2

    公开(公告)日：2009-08-11

    申请号：US11265850

    申请日：2005-11-03

    申请人： Paul E. Finke ,  Sander G. Mills ,  Christopher W. Plummer ,  Shrenik K. Shah ,  Quang T. Truong

    发明人： Paul E. Finke ,  Sander G. Mills ,  Christopher W. Plummer ,  Shrenik K. Shah ,  Quang T. Truong

    IPC分类号： A61K31/55 ,  C07D405/00 ,  C07D413/00

    CPC分类号： C07D405/12 ,  C07D233/90

    摘要： The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

    摘要翻译： 使用本发明的化合物作为大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，特别是用于治疗，预防和抑制由大麻素-1（CB1）受体介导的疾病。 本发明涉及这些新化合物选择性拮抗大麻素-1（CB1）受体的用途。 因此，本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的精神药物。 血管意外和头部创伤，焦虑障碍，压力，癫痫，帕金森病和精神分裂症。 这些化合物也可用于治疗药物滥用障碍，特别是鸦片剂，酒精和尼古丁。 所述化合物还可用于治疗与过量食物摄入和与其相关的并发症相关的肥胖或进食障碍。 还要求新的结构式（I）化合物。

    Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists
    76.
    发明申请
    Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists 失效
    八氢吡喃[3,4-C]吡咯速激肽受体拮抗剂

    公开(公告)号：US20080108689A1

    公开(公告)日：2008-05-08

    申请号：US11792514

    申请日：2005-12-12

    申请人： Robert J. Devita ,  Jinlong Jiang ,  Sander G. Mills ,  Jonathan R. Young

    发明人： Robert J. Devita ,  Jinlong Jiang ,  Sander G. Mills ,  Jonathan R. Young

    IPC分类号： A61K31/407 ,  C07D491/052 ,  A61P43/00

    CPC分类号： C07D491/04

    摘要： The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

    摘要翻译： 本发明涉及可用作神经激肽-1（NK-1）受体拮抗剂，速激肽抑制剂，特别是物质P的某些氢吡喃并吡咯烷化合物。本发明还涉及包含这些化合物作为活性成分的药物组合物和 使用化合物及其制剂治疗某些疾病，包括呕吐，尿失禁，抑郁和焦虑。

    Substituted imidazoles as cannabinoid receptor modulators
    78.
    发明授权
    Substituted imidazoles as cannabinoid receptor modulators 失效

    公开(公告)号：US07057051B2

    公开(公告)日：2006-06-06

    申请号：US10198442

    申请日：2002-07-17

    申请人： Paul E. Finke ,  Sander G. Mills ,  Christopher W. Plummer ,  Shrenik K. Shah ,  Quang T. Truong

    发明人： Paul E. Finke ,  Sander G. Mills ,  Christopher W. Plummer ,  Shrenik K. Shah ,  Quang T. Truong

    IPC分类号： C07D233/28

    CPC分类号： C07D405/12 ,  C07D233/90

    摘要： The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.